retatrutide clinical trial results 2024 Incretin-based therapies for the treatment of obesity-related diseases Retatrutide Shows 28% Weight Loss
Description
It made doctors hesitate
Triple-Hormone-Receptor Agonist Retatrutide for Obesity A Phase 2 Trial. The New England Journal of Medicine.
Unprecedented in medical history is going to be a term used OFTEN in the next 6 months as these other trials report out
The Bottom Line Retatrutide creates the deficit
Aroda, MD, and Melanie Davies, CBE, MBChB, MD, FRCP, FRCGP, FMedSci, will review the latest data for a novel oral glucagon-like peptide-1 receptor agonist in people living with with type 2 diabetes or overweight or obesity
How to Inject Retatrutide: Frequently Asked Questions Where is best to inject retatrutide
